Examkin

Question

Difficulty: MediumPharmacologic Interventions

A 7474-year-old man is evaluated on the inpatient medical ward. He was admitted 33 days ago for a severe exacerbation of chronic obstructive pulmonary disease. His home medications include warfarin for permanent atrial fibrillation and a tiotropium inhaler. On admission, he was started on intravenous methylprednisolone and oral levofloxacin. Today, he reports feeling much better with decreased dyspnea and minimal cough. His vital signs are stable, with a blood pressure of 128/76128/76 mm Hg and a heart rate of 7878/min. Routine morning laboratory results show an International Normalized Ratio (INR) of 7.27.2 (target 2.02.0-3.03.0). Physical examination reveals no petechiae, ecchymoses, or signs of gastrointestinal bleeding. Which of the following is the most appropriate next step in the management of this patient's pharmacotherapy?

  1. Omit the next one to two doses of warfarin, monitor the coagulation profile, and resume at a lower dose.Answer
  2. B
    Administer intravenous phytonadione and withhold the next dose of warfarin.
  3. C
    Administer four-factor prothrombin complex concentrate and withhold warfarin.
  4. D
    Withhold warfarin and administer phytonadione via the intramuscular route.
  5. E
    Discontinue levofloxacin, substitute with intravenous ceftriaxone, and continue the current warfarin dose.

Answer

The most appropriate next step is to omit the next one to two doses of warfarin, monitor the coagulation profile, and resume at a lower dose.
The correct answer involves withholding the next one to two doses of warfarin and monitoring the patient's coagulation profile. Current clinical guidelines state that for patients taking warfarin who present with an asymptomatic supratherapeutic INR between 4.54.5 and 1010, the routine use of phytonadione (Vitamin K) is not recommended. The safest and most effective approach is to hold warfarin until the INR falls back into the therapeutic range (2.02.0-3.03.0), and then resume it at a lower dose if the interacting medications (in this case, levofloxacin and methylprednisolone) are continued.

Step-by-Step Solution

1
Analyze the patient's clinical presentation and laboratory results.
The patient has an asymptomatic supratherapeutic INR of 7.2 without any signs of active bleeding.
Determining the presence or absence of active bleeding is the critical branching point in managing warfarin-associated coagulopathy.
2
Identify the likely cause of the coagulopathy.
The recent addition of levofloxacin and methylprednisolone caused a pharmacokinetic interaction, inhibiting warfarin metabolism and altering gut flora.
Understanding the etiology helps guide future dose adjustments once the INR returns to the therapeutic range.
3
Apply evidence-based guidelines for supratherapeutic INR reversal.
For an INR between 4.5 and 10 without bleeding, guidelines recommend holding 1-2 doses of warfarin rather than administering pharmacological reversal agents.
Routine use of Vitamin K in this range provides no outcome benefit and can cause warfarin resistance, while PCC is exclusively for life-threatening hemorrhage.

Key Concept

Management of supratherapeutic INR without bleeding
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic